Dual proinflammatory and antiviral properties of pulmonary eosinophils in respiratory syncytial virus vaccine-enhanced disease

Yung Chang Su, Dijana Townsend, Lara J. Herrero, Ali Zaid, Michael S. Rolph, Michelle E. Gahan, Michelle A. Nelson, Penny A. Rudd, Klaus I. Matthaei, Paul S. Foster, Lindsay Dent, Ralph A. Tripp, James Lee, Ljubov Simson, Suresh Mahalingam

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Human respiratory syncytial virus (RSV) is a major cause of morbidity and severe lower respiratory tract disease in the elderly and very young, with some infants developing bronchiolitis, recurrent wheezing, and asthma following infection. Previous studies in humans and animal models have shown that vaccination with formalin-inactivated RSV (FI-RSV) leads to prominent airway eosinophilic inflammation following RSV challenge; however, the roles of pulmonary eosinophilia in the antiviral response and in disease pathogenesis are inadequately understood. In vivo studies in mice with eotaxin and/or interleukin 5 (IL-5) deficiency showed that FI-RSV vaccination did not lead to enhanced pulmonary disease, where following challenge there were reduced pulmonary eosinophilia, inflammation, Th2-type cytokine responses, and altered chemokine (TARC and CCL17) responses. In contrast to wild-type mice, RSV was recovered at high titers from the lungs of eotaxin- and/or IL-5-deficient mice. Adoptive transfer of eosinophils to FI-RSV-immunized eotaxin- and IL-5-deficient (double-deficient) mice challenged with RSV was associated with potent viral clearance that was mediated at least partly through nitric oxide. These studies show that pulmonary eosinophilia has dual outcomes: one linked to RSV-induced airway inflammation and pulmonary pathology and one with innate features that contribute to a reduction in the viral load.

Original languageEnglish (US)
Pages (from-to)1564-1578
Number of pages15
JournalJournal of Virology
Volume89
Issue number3
DOIs
StatePublished - 2015

Fingerprint

Respiratory Syncytial Virus Vaccines
antiviral properties
Respiratory Syncytial Viruses
eosinophils
Eosinophils
Antiviral Agents
Pulmonary Eosinophilia
interleukin-5
eosinophilia
lungs
vaccines
Interleukin-5
Lung
viruses
formalin
Formaldehyde
inflammation
mice
respiratory tract diseases
Pneumonia

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Su, Y. C., Townsend, D., Herrero, L. J., Zaid, A., Rolph, M. S., Gahan, M. E., ... Mahalingam, S. (2015). Dual proinflammatory and antiviral properties of pulmonary eosinophils in respiratory syncytial virus vaccine-enhanced disease. Journal of Virology, 89(3), 1564-1578. https://doi.org/10.1128/JVI.01536-14

Dual proinflammatory and antiviral properties of pulmonary eosinophils in respiratory syncytial virus vaccine-enhanced disease. / Su, Yung Chang; Townsend, Dijana; Herrero, Lara J.; Zaid, Ali; Rolph, Michael S.; Gahan, Michelle E.; Nelson, Michelle A.; Rudd, Penny A.; Matthaei, Klaus I.; Foster, Paul S.; Dent, Lindsay; Tripp, Ralph A.; Lee, James; Simson, Ljubov; Mahalingam, Suresh.

In: Journal of Virology, Vol. 89, No. 3, 2015, p. 1564-1578.

Research output: Contribution to journalArticle

Su, YC, Townsend, D, Herrero, LJ, Zaid, A, Rolph, MS, Gahan, ME, Nelson, MA, Rudd, PA, Matthaei, KI, Foster, PS, Dent, L, Tripp, RA, Lee, J, Simson, L & Mahalingam, S 2015, 'Dual proinflammatory and antiviral properties of pulmonary eosinophils in respiratory syncytial virus vaccine-enhanced disease', Journal of Virology, vol. 89, no. 3, pp. 1564-1578. https://doi.org/10.1128/JVI.01536-14
Su, Yung Chang ; Townsend, Dijana ; Herrero, Lara J. ; Zaid, Ali ; Rolph, Michael S. ; Gahan, Michelle E. ; Nelson, Michelle A. ; Rudd, Penny A. ; Matthaei, Klaus I. ; Foster, Paul S. ; Dent, Lindsay ; Tripp, Ralph A. ; Lee, James ; Simson, Ljubov ; Mahalingam, Suresh. / Dual proinflammatory and antiviral properties of pulmonary eosinophils in respiratory syncytial virus vaccine-enhanced disease. In: Journal of Virology. 2015 ; Vol. 89, No. 3. pp. 1564-1578.
@article{919abdec253b40ffa95fa7206426c652,
title = "Dual proinflammatory and antiviral properties of pulmonary eosinophils in respiratory syncytial virus vaccine-enhanced disease",
abstract = "Human respiratory syncytial virus (RSV) is a major cause of morbidity and severe lower respiratory tract disease in the elderly and very young, with some infants developing bronchiolitis, recurrent wheezing, and asthma following infection. Previous studies in humans and animal models have shown that vaccination with formalin-inactivated RSV (FI-RSV) leads to prominent airway eosinophilic inflammation following RSV challenge; however, the roles of pulmonary eosinophilia in the antiviral response and in disease pathogenesis are inadequately understood. In vivo studies in mice with eotaxin and/or interleukin 5 (IL-5) deficiency showed that FI-RSV vaccination did not lead to enhanced pulmonary disease, where following challenge there were reduced pulmonary eosinophilia, inflammation, Th2-type cytokine responses, and altered chemokine (TARC and CCL17) responses. In contrast to wild-type mice, RSV was recovered at high titers from the lungs of eotaxin- and/or IL-5-deficient mice. Adoptive transfer of eosinophils to FI-RSV-immunized eotaxin- and IL-5-deficient (double-deficient) mice challenged with RSV was associated with potent viral clearance that was mediated at least partly through nitric oxide. These studies show that pulmonary eosinophilia has dual outcomes: one linked to RSV-induced airway inflammation and pulmonary pathology and one with innate features that contribute to a reduction in the viral load.",
author = "Su, {Yung Chang} and Dijana Townsend and Herrero, {Lara J.} and Ali Zaid and Rolph, {Michael S.} and Gahan, {Michelle E.} and Nelson, {Michelle A.} and Rudd, {Penny A.} and Matthaei, {Klaus I.} and Foster, {Paul S.} and Lindsay Dent and Tripp, {Ralph A.} and James Lee and Ljubov Simson and Suresh Mahalingam",
year = "2015",
doi = "10.1128/JVI.01536-14",
language = "English (US)",
volume = "89",
pages = "1564--1578",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "3",

}

TY - JOUR

T1 - Dual proinflammatory and antiviral properties of pulmonary eosinophils in respiratory syncytial virus vaccine-enhanced disease

AU - Su, Yung Chang

AU - Townsend, Dijana

AU - Herrero, Lara J.

AU - Zaid, Ali

AU - Rolph, Michael S.

AU - Gahan, Michelle E.

AU - Nelson, Michelle A.

AU - Rudd, Penny A.

AU - Matthaei, Klaus I.

AU - Foster, Paul S.

AU - Dent, Lindsay

AU - Tripp, Ralph A.

AU - Lee, James

AU - Simson, Ljubov

AU - Mahalingam, Suresh

PY - 2015

Y1 - 2015

N2 - Human respiratory syncytial virus (RSV) is a major cause of morbidity and severe lower respiratory tract disease in the elderly and very young, with some infants developing bronchiolitis, recurrent wheezing, and asthma following infection. Previous studies in humans and animal models have shown that vaccination with formalin-inactivated RSV (FI-RSV) leads to prominent airway eosinophilic inflammation following RSV challenge; however, the roles of pulmonary eosinophilia in the antiviral response and in disease pathogenesis are inadequately understood. In vivo studies in mice with eotaxin and/or interleukin 5 (IL-5) deficiency showed that FI-RSV vaccination did not lead to enhanced pulmonary disease, where following challenge there were reduced pulmonary eosinophilia, inflammation, Th2-type cytokine responses, and altered chemokine (TARC and CCL17) responses. In contrast to wild-type mice, RSV was recovered at high titers from the lungs of eotaxin- and/or IL-5-deficient mice. Adoptive transfer of eosinophils to FI-RSV-immunized eotaxin- and IL-5-deficient (double-deficient) mice challenged with RSV was associated with potent viral clearance that was mediated at least partly through nitric oxide. These studies show that pulmonary eosinophilia has dual outcomes: one linked to RSV-induced airway inflammation and pulmonary pathology and one with innate features that contribute to a reduction in the viral load.

AB - Human respiratory syncytial virus (RSV) is a major cause of morbidity and severe lower respiratory tract disease in the elderly and very young, with some infants developing bronchiolitis, recurrent wheezing, and asthma following infection. Previous studies in humans and animal models have shown that vaccination with formalin-inactivated RSV (FI-RSV) leads to prominent airway eosinophilic inflammation following RSV challenge; however, the roles of pulmonary eosinophilia in the antiviral response and in disease pathogenesis are inadequately understood. In vivo studies in mice with eotaxin and/or interleukin 5 (IL-5) deficiency showed that FI-RSV vaccination did not lead to enhanced pulmonary disease, where following challenge there were reduced pulmonary eosinophilia, inflammation, Th2-type cytokine responses, and altered chemokine (TARC and CCL17) responses. In contrast to wild-type mice, RSV was recovered at high titers from the lungs of eotaxin- and/or IL-5-deficient mice. Adoptive transfer of eosinophils to FI-RSV-immunized eotaxin- and IL-5-deficient (double-deficient) mice challenged with RSV was associated with potent viral clearance that was mediated at least partly through nitric oxide. These studies show that pulmonary eosinophilia has dual outcomes: one linked to RSV-induced airway inflammation and pulmonary pathology and one with innate features that contribute to a reduction in the viral load.

UR - http://www.scopus.com/inward/record.url?scp=84921501593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921501593&partnerID=8YFLogxK

U2 - 10.1128/JVI.01536-14

DO - 10.1128/JVI.01536-14

M3 - Article

C2 - 25410867

AN - SCOPUS:84921501593

VL - 89

SP - 1564

EP - 1578

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 3

ER -